Karrison TG - Search Results

1

Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.

Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG 3rd, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Kindler HL, et al. Among authors: karrison tg. J Clin Oncol. 2012 Jul 10;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869. Epub 2012 Jun 4. J Clin Oncol. 2012. PMID: 22665541 Free PMC article. Clinical Trial.

2

The interaction of 5-fluorouracil, hydroxyurea, and radiation in two human head and neck cancer cell lines.

Vokes EE, Beckett M, Karrison T, Weichselbaum RR. Vokes EE, et al. Oncology. 1992;49(6):454-60. doi: 10.1159/000227092. Oncology. 1992. PMID: 1465284

3

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study.

Karrison TG, Vogelzang NJ. Karrison TG, et al. Cancer. 1999 Aug 1;86(3):546-7. doi: 10.1002/(sici)1097-0142(19990801)86:3<546::aid-cncr28>3.0.co;2-g. Cancer. 1999. PMID: 10430267 No abstract available.

4

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.

Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. Iyer L, et al. Pharmacogenomics J. 2002;2(1):43-7. doi: 10.1038/sj.tpj.6500072. Pharmacogenomics J. 2002. PMID: 11990381

5

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.

Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Stadler WM, et al. J Urol. 2003 Oct;170(4 Pt 1):1141-5. doi: 10.1097/01.ju.0000086829.74971.4a. J Urol. 2003. PMID: 14501711 Clinical Trial.

6

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.

Vogelzang NJ, Karrison T, Stadler WM, Garcia J, Cohn H, Kugler J, Troeger T, Giannone L, Arrieta R, Ratain MJ, Vokes EE. Vogelzang NJ, et al. Cancer. 2004 Jan 1;100(1):65-71. doi: 10.1002/cncr.11867. Cancer. 2004. PMID: 14692025 Free article. Clinical Trial.

7

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ. Innocenti F, et al. J Clin Oncol. 2004 Apr 15;22(8):1382-8. doi: 10.1200/JCO.2004.07.173. Epub 2004 Mar 8. J Clin Oncol. 2004. PMID: 15007088

8

9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.

Kindler HL, Avadhani A, Wade-Oliver K, Karrison T, Mani S, Vokes EE. Kindler HL, et al. Invest New Drugs. 2004 Aug;22(3):323-7. doi: 10.1023/B:DRUG.0000026259.28395.c2. Invest New Drugs. 2004. PMID: 15122080 Clinical Trial.

9

A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.

Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, Wright R, Karrison T, Vokes EE. Stadler WM, et al. Clin Cancer Res. 2004 May 15;10(10):3365-70. doi: 10.1158/1078-0432.CCR-03-0404. Clin Cancer Res. 2004. PMID: 15161690 Clinical Trial.

10

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.

Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Zimmerman TM, et al. J Clin Oncol. 2004 Dec 1;22(23):4816-22. doi: 10.1200/JCO.2004.03.200. J Clin Oncol. 2004. PMID: 15570084 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

252 results

Search Page